Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Molecular Oncology|June 10, 2014
Drug resistance to targeted therapies: déjà vu all over againFloris H Groenendijk, René BernardsBreast Cancer Research and Treatment|August 6, 2013
Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnosticsFloris H Groenendijk, Wilbert Zwart, Arno Floore, et al.Breast (Edinburgh, Scotland)|January 9, 2018
A nationwide registry-based cohort study of the MammaPrint genomic risk classifier in invasive breast cancerFloris H Groenendijk, Agnes Jager, Fatima Cardoso, et al.Journal of Cutaneous Pathology|July 6, 2020
Trichoblastic carcinosarcoma with panfollicular differentiation (panfollicular carcinosarcoma) and CTNNB1 (beta-catenin) mutationJenny Giang, Asok Biswas, Antien L Mooyaart, et al.International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|March 5, 2019
An Exceptional Vulvar Tumor: Myeloid Sarcoma of the Labia MajoraKarishma P Ramlakhan, Floris H Groenendijk, Mark-David Levin, et al.Pathology|April 12, 2025
HER2-low across solid tumours: different incidences and definitionsXimena Baez-Navarro, Floris H Groenendijk, Lindsey Oudijk, et al.NPJ Breast Cancer|April 25, 2019
Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancersFloris H Groenendijk, Tina Treece, Erin Yoder, et al.Journal of Gynecologic Oncology|January 24, 2025
Poor accuracy of endometrial sampling in patients with uterine carcinosarcomas: a nationwide analysisEveline N B Pham, Caroline B van den Berg, Rachel van Es, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 4, 2019
Ductal carcinoma in situ of the breast: immune cell composition according to subtypeMarie Colombe Agahozo, Mieke R van Bockstal, Floris H Groenendijk, et al.Journal of Neuro-Oncology|July 2, 2010
MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutationFloris H Groenendijk, Walter Taal, Hendrikus J Dubbink, et al.Pageof 3